| |
CD4 <200/μL
| CD4 ≧200/μL |
P value
|
CD4 <200/μL
| CD4 ≧200/μL |
P value
| |
|
Patient number, n
|
211
|
68
| |
145
|
71
| |
165
|
|
New/recurrent episodes of PCP, n
|
11
|
1
| |
6
|
1
| |
3
|
|
Time from discontinuation of prophylaxis to PCP, median, M
|
13.7 (2.2-92.4)
|
74.5
| |
22.8 (8.3-69.3)
|
-20.7
| | |
|
CD4 count when new PCP developed, median, cells/μl
|
33 (8-138)
|
9
| |
4 (1-40)
|
-13
| |
5 (0-87)
|
|
Total observation duration, PY
|
366
|
234
| |
241
|
210
| |
104
|
|
Incidence of new/recurrent PCP, per 100 PY (95% CI)
|
3.00 (1.26-4.76)
|
0.43 (0.01-2.38)
|
0.03
|
2.49 (0.91-5.42)
|
0.48 (0.01-2.65)
|
0.13
|
2.88 (0.59-8.43)
|
|
Episodes of bacterial infection, n
|
53
|
13
| |
21
|
7
| |
22
|
|
Incidence of bacterial infection, per 100 PY (95% CI)
|
14.48 (10.85-18.94)
|
5.56 (2.96-9.50)
|
<0.001
|
8.71 (5.39-13.32)
|
3.33 (1.34-6.87)
|
0.03
|
21.16 (13.35-32.03)
|
|
Episodes of parasitic infection, n
|
2
|
0
| |
2
|
0
| |
2
|
|
Incidence of parasitic infection, per 100 PY (95% CI)
|
0.54 (0.07-1.97)
|
0
| |
0.83 (0.10-3.00)
|
0
| |
1.92 (0.23-6.95)
|
|
Death, n (%)
|
23 (10.9)
|
4 (5.9)
|
0.35
|
8 (5.5)
|
1 (1.4)
|
0.28
|
22 (13.3)
|
|
Patients lost to follow-up, n (%)
|
40 (19.0)
|
7 (10.3)
|
0.19
|
16 (11.0)
|
8 (11.3)
|
1
|
44 (26.6)
|
